Back to search
FDAFDA · Food and drugs·Recall number D-0402-2026

CUROSURF (poractant alfa), 240 mg, Intratracheal Suspension, 3L Single-dose-Vial, Rx only, Chiesi USA, Inc, Cary, NC 27518, NDC 10122-510-03.

Published April 1, 2026 · Recall initiated: March 17, 2026

Summary

FDA records drug Class II recall D-0402-2026, published April 1, 2026 and initiated March 17, 2026. Recalling firm: Chiesi USA, Inc.; Status: Ongoing; Reported quantity: 7,235 vials; Lot: Lot #: 1213748, Exp. Date 09/2026; 1215076, 1215077, Exp. Date 10/26. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email if CUROSURF has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CUROSURF
Manufacturer
Chiesi USA, Inc.
Distributor
Nationwide within the United States
Lot
Lot #: 1213748, Exp. Date 09/2026; 1215076, 1215077, Exp. Date 10/26.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was CUROSURF (poractant alfa), 240 mg, Intratracheal Suspension, 3L Single-dose-Vial, Rx only, Chiesi USA, Inc, Cary, NC 27518, NDC 10122-510-03. recalled?

Yes. FDA published recall D-0402-2026 on April 1, 2026. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CUROSURF.